Hines Sonia, Steels Elizabeth, Chang Anne, Gibbons Kristen
Evidence in Practice Unit, Mater Misericordiae Limited. Queensland Centre for Evidence-Based Nursing & Midwifery: a Joanna Briggs Centre of Excellence, South Brisbane, Australia.
Cochrane Database Syst Rev. 2018 Mar 10;3(3):CD007598. doi: 10.1002/14651858.CD007598.pub3.
BACKGROUND: Postoperative nausea and vomiting (PONV) is a common, unpleasant phenomenon and current therapies are not always effective for all patients. Aromatherapy has been suggested as an addition to the available treatment strategies. This review was originally published in 2012 and updated in 2017. OBJECTIVES: The main objective was to establish the efficacy and safety of aromatherapy comparable to standard pharmacological treatments for PONV in adults and children. SEARCH METHODS: We searched CENTRAL; MEDLINE; Embase; CINAHL; CAM on PubMed; Informit; LILACS; and ISI Web of Science as well as grey literature sources and the reference lists of retrieved articles up to March 2017. The original search was performed in August 2011. SELECTION CRITERIA: We included all randomized controlled trials (RCTs) and controlled clinical trials (CCTs) where aromatherapy was used to treat PONV. Interventions were all types of aromatherapy compared to placebo or with standard antiemetics. Primary outcomes were severity and duration of PONV. Secondary outcomes were adverse reactions, use of rescue antiemetics and patient satisfaction. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed risk of bias in the included studies and extracted data. For dichotomous outcome variables, we used a random-effects model and calculated risk ratio (RR) with associated 95% confidence interval (95% CI). For continuous outcome variables, we used a random-effects model and calculated standardized mean difference (SMD) with associated 95% CI. We used the GRADE software to compile 'Summary of findings' tables. MAIN RESULTS: We included seven new studies with 663 participants in the 2017 update; five RCTs and two CCTs. These were added to the nine previously included studies (six RCTs and three CCTs with a total of 373 participants) for a total of 16 included studies and 1036 participants in this updated review. The mean age and range data for all participants were not reported for all studies. We identified two registered trials that met the inclusion criteria for this review; however there are no results for these studies yet.Overall, the GRADE assessment of evidence quality ranged from moderate to very low. The method of randomization in 11 of the 12 included RCTs was explicitly stated and adequate. Incomplete or methodologically diverse reporting of data affected the completeness of the analysis. Data on additional aromatherapies were added in the 2017 update (blended aromatherapy products, and peppermint products). Heterogeneity of outcome measures and time points between studies affected the completeness of the analysis.In the summary of the findings of six studies, we did not find aromatherapy to be effective in reducing nausea severity in comparison to placebo (SMD -0.22, 95% CI -0.63 to 0.18, P value = 0.28, 241 participants, level of evidence: low). Those participants receiving aromatherapy were no more likely to be free of nausea at the end of the treatment period than those receiving placebo (RR 3.25, 95% CI 0.31 to 34.33, P value = 0.33, 4 trials, 193 participants, evidence level: very low), however they were less likely to require rescue antiemetics (RR 0.60, 95% CI 0.37 to 0.97, P value = 0.04, 7 trials, 609 participants, evidence level: low). There were no data reported on adverse events or patient satisfaction for this comparison.A specific comparison of peppermint aromatherapy to placebo did not show evidence of an effect on nausea severity at five minutes post-treatment in the pooled results (SMD -0.18, 95% CI -0.86 to 0.49, P value = 0.59, 4 trials, 115 participants, evidence level: low). There were no data reported on nausea duration, use of rescue antiemetics, adverse events or patient satisfaction for this comparison.When we pooled studies comparing isopropyl alcohol to standard antiemetic treatment in a GRADE summary of findings, in terms of nausea duration, there was a significant effect on the time in minutes to a 50% reduction in nausea scores (SMD -1.10, 95% CI -1.43 to -0.78, P value < 0.00001, 3 trials, 176 participants, evidence level: moderate). Fewer participants who received isopropyl alcohol required rescue antiemetics (RR 0.67, 95% CI 0.46 to 0.98, P value = 0.04, 215 participants, 4 trials, evidence level: moderate). Two studies with 172 participants measured patient satisfaction; there were high levels of satisfaction across both aromatherapy and standard treatment groups and no differences found (evidence level: low). There were no data reported on nausea severity or adverse events for this comparison.There was no difference in effectiveness between isopropyl alcohol vapour inhalation and placebo for reducing the proportion of participants requiring rescue antiemetics (RR 0.39, 95% CI 0.12 to 1.24, P value = 0.11, 291 participants, 4 trials, evidence level: very low). There were no data reported on nausea severity, nausea duration, adverse events or patient satisfaction for this comparison. AUTHORS' CONCLUSIONS: Overall, for nausea severity at the end of treatment, aromatherapy may have similar effectiveness to placebo and similar numbers of participants were nausea-free. However, this finding is based on low-quality evidence and therefore very uncertain. Low-quality evidence also suggests that participants who received aromatherapy may need fewer antiemetic medications, but again, this is uncertain. Participants receiving either aromatherapy or antiemetic medications may report similar levels of satisfaction with their treatment, according to low-quality evidence.
背景:术后恶心呕吐(PONV)是一种常见的令人不适的现象,目前的治疗方法并非对所有患者都有效。芳香疗法被建议作为现有治疗策略的补充。本综述最初发表于2012年,并于2017年更新。 目的:主要目的是确定芳香疗法在治疗成人和儿童PONV方面与标准药物治疗相当的疗效和安全性。 检索方法:我们检索了CENTRAL、MEDLINE、Embase、CINAHL、PubMed上的补充和替代医学数据库、Informit、LILACS以及科学网,以及灰色文献来源和截至2017年3月检索到的文章的参考文献列表。最初的检索于2011年8月进行。 选择标准:我们纳入了所有使用芳香疗法治疗PONV的随机对照试验(RCT)和对照临床试验(CCT)。干预措施为与安慰剂或标准止吐药相比的所有类型的芳香疗法。主要结局为PONV的严重程度和持续时间。次要结局为不良反应、急救止吐药的使用和患者满意度。 数据收集与分析:两位综述作者独立评估纳入研究的偏倚风险并提取数据。对于二分结局变量,我们使用随机效应模型并计算风险比(RR)及相关的95%置信区间(95%CI)。对于连续结局变量,我们使用随机效应模型并计算标准化均数差(SMD)及相关的95%CI。我们使用GRADE软件编制“结果总结”表。 主要结果:在2017年的更新中,我们纳入了七项新研究,共663名参与者;五项RCT和两项CCT。这些研究被添加到之前纳入的九项研究(六项RCT和三项CCT,共373名参与者)中,本次更新综述总共纳入了16项研究和1036名参与者。并非所有研究都报告了所有参与者的平均年龄和年龄范围数据。我们确定了两项符合本综述纳入标准的注册试验;然而,这些研究尚无结果。总体而言,证据质量的GRADE评估从中等至极低不等。12项纳入的RCT中有11项明确说明了随机化方法且方法恰当。数据报告不完整或方法多样影响了分析的完整性。2017年的更新中增加了关于其他芳香疗法的数据(混合芳香疗法产品和薄荷产品)。研究之间结局测量和时间点的异质性影响了分析的完整性。在六项研究的结果总结中,我们发现与安慰剂相比,芳香疗法在减轻恶心严重程度方面无效(SMD -0.22,95%CI -0.63至0.18,P值 = 0.28,241名参与者,证据级别:低)。接受芳香疗法的参与者在治疗结束时无恶心的可能性并不高于接受安慰剂的参与者(RR 3.25,95%CI 0.31至34.33,P值 = 0.33,4项试验,193名参与者,证据级别:极低),然而他们需要急救止吐药的可能性较小(RR 0.60,95%CI 0.37至0.97,P值 = 0.04,7项试验,609名参与者,证据级别:低)。对于此比较,未报告关于不良事件或患者满意度的数据。薄荷芳香疗法与安慰剂的具体比较在汇总结果中未显示出对治疗后五分钟恶心严重程度有影响的证据(SMD -0.18,95%CI -0.86至0.49,P值 = 0.59,4项试验,115名参与者,证据级别:低)。对于此比较,未报告关于恶心持续时间、急救止吐药的使用、不良事件或患者满意度的数据。当我们在GRADE结果总结中汇总比较异丙醇与标准止吐药治疗的研究时,就恶心持续时间而言,对恶心评分降低50%所需的分钟数有显著影响(SMD -1.10,95%CI -1.43至 -0.78,P值 < 0.00001,3项试验,176名参与者,证据级别:中等)。接受异丙醇治疗的参与者中需要急救止吐药的较少(RR 0.67,95%CI 0.46至0.98,P值 = 0.04,215名参与者,4项试验,证据级别:中等)。两项共172名参与者的研究测量了患者满意度;芳香疗法组和标准治疗组的满意度都很高,且未发现差异(证据级别:低)。对于此比较,未报告关于恶心严重程度或不良事件的数据。异丙醇蒸汽吸入与安慰剂在减少需要急救止吐药的参与者比例方面的有效性没有差异(RR 0.39,95%CI 0.12至1.24,P值 = 0.11,291名参与者,4项试验,证据级别:极低)。对于此比较,未报告关于恶心严重程度、恶心持续时间、不良事件或患者满意度的数据。 作者结论:总体而言,对于治疗结束时的恶心严重程度,芳香疗法可能与安慰剂具有相似的有效性,且无恶心的参与者数量相似。然而,这一发现基于低质量证据,因此非常不确定。低质量证据还表明,接受芳香疗法的参与者可能需要较少的止吐药物,但同样,这也不确定。根据低质量证据,接受芳香疗法或止吐药物治疗的参与者可能对其治疗报告相似的满意度水平。
Cochrane Database Syst Rev. 2018-3-10
Cochrane Database Syst Rev. 2018-9-21
Cochrane Database Syst Rev. 2018-2-6
Cochrane Database Syst Rev. 2018-6-4
Cochrane Database Syst Rev. 2018-4-18
Cochrane Database Syst Rev. 2022-10-17
Cochrane Database Syst Rev. 2022-6-9
Cochrane Database Syst Rev. 2005-7-20
Cochrane Database Syst Rev. 2021-11-16
Cochrane Database Syst Rev. 2021-9-14
Front Psychiatry. 2025-3-31
J Altern Complement Med. 2017-3
BMC Complement Altern Med. 2016-11-9
Complement Ther Med. 2015-12
J Perianesth Nurs. 2015-10
Nurs Midwifery Stud. 2015-6
Res Synth Methods. 2010-11-21